Aspira Women’s Health Inc. Announces Pricing of $9.0 Million Public Offering

Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced the pricing of a public offering of 12,000,000 shares of common stock and 12,000,000 accompanying warrants at a combined price of $0.75 per share. The company expects to raise approximately $9.0 million from the offering, which is set to close on August 25, 2022. Proceeds will be utilized for working capital, product expansion, and strategic partnerships. The offering is registered under SEC File No. 333-252267.

Positive

• The offering is expected to generate approximately $9.0 million to support business growth.
• Funds will be used for product portfolio expansion and commercialization efforts.

Negative

• Common stock dilution due to the issuance of 12,000,000 shares.
• Warrants will require additional capital if exercised, impacting per-share value.

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (Nasdaq: AWH) (“Aspira”), a bio-analytical based women’s health company focused on gynecologic disease, today announced the pricing of the previously announced underwritten public offering of 12,000,000 shares of its common stock and warrants to purchase an aggregate of 12,000,000 shares of its common stock at a combined price to the public of $0.75 per share of common stock and accompanying warrant. Each warrant will have an exercise price of $0.88 per share and will be exercisable during the period commencing on the closing date of the offering and ending five years following such date. All of the securities are being offered by Aspira.

William Blair & Company, L.L.C. is acting as the sole book-running manager for the proposed offering.

The offering is expected to close on August 25, 2022, subject to customary closing conditions.

Gross proceeds from the offering are expected to be $9.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Aspira. Aspira intends to use the net proceeds from the offering for working capital and other general corporate purposes, including product portfolio expansion and commercialization. Aspira may also use a portion of the net proceeds from the offering to invest in complimentary businesses, strategic partnerships, technologies or other intellectual property.

The offering is being made pursuant to a shelf registration statement (File No. 333-252267) previously filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement, dated August 22, 2022, and accompanying prospectus, dated January 28, 2021, relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. To obtain a copy of the final prospectus supplement for the offering (when available), please contact William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at 1-800-621-0687 or by e-mail at prospectus@williamblair.com.

This press release is for informational purposes only and shall not constitute an offer to sell or a solicitation of an offer to buy securities in any state or other jurisdiction in which such offer or sale is not permitted.

About Aspira Women’s Health Inc.
Aspira Women’s Health Inc. (Nasdaq: AWH) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1plus™ combines our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. Aspira GenetiX™ testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. The next generation of products in development include OVAWatch™ and EndoCheck™.

Forward Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, without limitation, statements regarding the completion of the proposed public offering, as well as the anticipated use of proceeds therefrom. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and satisfaction of customary closing conditions related to the proposed public offering, as well as risks and uncertainties inherent in Aspira’s business, including those described in the section entitled “Risk Factors” in Aspira’s Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by the section entitled “Risk Factors” in Aspira’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, and in Aspira’s other periodic filings with the SEC. The events and circumstances reflected in Aspira’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Aspira expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: 617-430-7577
Arr@lifesciadvisors.com

FAQ

What is the purpose of the offering by Aspira Women’s Health (AWH)?

The offering aims to raise funds for working capital, product portfolio expansion, and strategic partnerships.

When is the offering expected to close?

The offering is expected to close on August 25, 2022.

How much money is Aspira Women’s Health (AWH) expected to raise from the offering?

Aspira is expected to raise approximately $9.0 million from the offering.

What is the exercise price of the warrants associated with the offering?

The warrants have an exercise price of $0.88 per share.

How many shares are being offered in the Aspira Women’s Health (AWH) public offering?

The public offering includes 12,000,000 shares of common stock.